2021 EBMT Annual Meeting
Coverage of the 2021 EBMT Annual Meeting, held virtually March 14-17, 2021.
Narsoplimab Elicits Responses Across High-Risk HSCT-TMA Subtypes
March 16th 2021The MASP-2 inhibitor narsoplimab demonstrated high response rates and a significant improvement in laboratory markers and organ function irrespective of subgroup in adult patients with high-risk hematopoietic stem cell transplant–associated thrombotic microangiopathy.
AB-205 Shows Tolerability, Robust Effects in Patients With Lymphoma Undergoing HDT-ASCT
March 16th 2021The engineered cord endothelial cell product AB-205 showed an encouraging safety profile along with robust effects in eliminating oral/gastrointestinal severe regimen-related toxicities in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.
Omidubicel Showcases Promising Outcomes in High-Risk Hematologic Cancers Following Myeloablation
March 15th 2021Omidubicel was associated with a significantly improved median time to neutrophil engraftment compared with standard umbilical cord blood transplantation in patients with high-risk hematologic malignancies.
